Results 181 to 190 of about 817,997 (230)

Metabolism of monoamine oxidase inhibitors

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989
1. Despite the fact that monoamine oxidase inhibitors have been used clinically and in animal experiments for many years, much still remains unknown about their metabolism. An overview of the metabolic aspects of several monoamine oxidase inhibitors, including phenelzine, tranylcypromine, pheniprazine, pargyline and deprenyl, is presented. 2.
G B, Baker, R T, Coutts
openaire   +2 more sources

Monoamine oxidase inhibitors in hypertension

The American Journal of Cardiology, 1960
Abstract 1. 1. A survey of the literature reveals that the monoamine oxidase inhibitors, 1-isonicotinyl-2-isopropyl hydrazine (iproniazid, Marsilid), betaphenylisopropyl-hydrazine hydrochloride (JB 516, Catron®) and DL-serine-N2-isopropyl hydrazide monohydrochloride (RO4–1038)have antihypertensive effects in man. 2. 2.
M H, MAXWELL, H, BERNSTEIN, S, ROTH, C R, KLEEMAN   +3 more
openaire   +2 more sources

Pyrogens and Monoamine Oxidase Inhibitors

Nature, 1966
MANY nerve terminals within the hypothalamus contain either noradrenaline or 5-hydroxytryptamine (5-HT) (ref. 1). It has been suggested that these amines may play a part in the thermo-regulatory pathways2–4.
K E, Cooper, W I, Cranston
openaire   +2 more sources

New Inhibitor of Monoamine Oxidase

Nature, 1960
THE following is the initial report of a structurally unique monoamine oxidase inhibitor, N-benzyl-N-methyl-2-propynylamine hydrochloride (A19120). This work includes in vitro action of this inhibitor on rat liver mitochondria as well as in vivo inhibition of monoamine oxidase of mouse brain and the liver.
J D, TAYLOR, A A, WYKES, Y C, GLADISH, W B, MARTIN   +3 more
openaire   +2 more sources

Inhibitor Design for Monoamine Oxidases

Current Pharmaceutical Design, 2013
Flavin-containing monoamine oxidases (MAO A and MAO B) located on the outer membrane of mitochondria oxidise amines and generate hydrogen peroxide. Inhibitors alleviate depression by increasing neurotransmitter levels in the brain. Elevation of neurotransmitters,although an established outcome, is a delicate balance because complete lack of MAO A is ...
openaire   +2 more sources

Metabolism of Monoamine Oxidase Inhibitors

Cellular and Molecular Neurobiology, 1999
1. The principal routes of metabolism of the following monoamine oxidase inhibitors (MAOIs) are described: phenelzine, tranylcypromine, pargyline, deprenyl, moclobemide, and brofaromine. 2. Acetylation of phenelzine appears to be a minor metabolic pathway.
G B, Baker, L J, Urichuk, K F, McKenna, S H, Kennedy   +3 more
openaire   +2 more sources

Monoamine oxidase inhibitor overdose

Annals of Emergency Medicine, 1984
Described is the clinical course of a 26-year-old woman who died following an overdose of the MAO inhibitor phenelzine. Signs and symptoms of toxicity were delayed in onset. Initial findings of excessive neuromuscular activity were followed by severe hyperthermia, coma, cardiovascular collapse, acute renal failure, hemolysis, rhabdomyolysis, and ...
C H, Linden, B H, Rumack, C, Strehlke
openaire   +2 more sources

Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs

Life Sciences, 1974
Publisher Summary This chapter discusses the monoamine oxidases (MAO) and the MAO inhibitor drugs. Phenylethylamines and indolethylamines appear to be the endogenous substrates for tissue MAO. The m-O-methylated catecholamine metabolites have lower values than the parent amines.
N H, Neff, H Y, Yang
openaire   +2 more sources

Anesthesia and Monoamine Oxidase Inhibitors

JAMA: The Journal of the American Medical Association, 1989
To the Editor.— I wish to register my strong disagreement with your consultants Drs Hirshman and Lindeman 1 and their assertion that it is safe to administer an elective anesthetic to a patient receiving monoamine oxidase inhibitors. 1 I believe that theirs is a minority viewpoint.
openaire   +2 more sources

Abuse of Monoamine Oxidase Inhibitors

The American Journal of Drug and Alcohol Abuse, 1992
Monoamine oxidase inhibitors, like other antidepressants, generally are considered free of risk for abuse. There is, however, some evidence that MAOIs possess dependence and abuse potential for some patients. We will review the available literature and describe three current cases. Recommendations for treatment are discussed briefly.
G, Baumbacher, M S, Hansen
openaire   +2 more sources